HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

Life Sciences

Volumn 71, Issue 20, 2002, Pages 2403-2412

  Sone, Hirohito ^a   Takahashi, Akimitsu ^a   Shimano, Hitoshi ^a   Ishibashi, Shun ^b   Yoshino, Gen ^c   Morisaki, Nobuhiro ^d   Saito, Yasushi ^d   Kawazu, Shoji ^e   Teramoto, Tamio ^f   Fujita, Toshiro ^g   Shiba, Teruo ^h   Iwamoto, Yasuhiko ⁱ   Kuzuya, Nobuaki ^j   Akanuma, Yasuo ^j   Yamada, Nobuhiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f TEIKYO UNIVERSITY   (Japan)

^g UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^h MITSUI MEMORIAL HOSPITAL   (Japan)

ⁱ Tokyo Women's University   (Japan)

^j INSTITUTE FOR ADULT DISEASES   (Japan)

more..

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitor; Dyslipidemia; Pitavastatin; Remnant like particle cholesterol (RLP C); Small dense low density lipoprotein (LDL); Type 2 diabetes

Indexed keywords

CHOLESTEROL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION FUNCTION; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED;

EID: 18644373317     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02038-6     Document Type: Article

References (31)

1. Hsueh W.A., Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med. 105(1A):1998;4S-14S.
2. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82(12A):67U-73U, 85U-86U.
3. Mykkanen L., Haffner S.M., Rainwater D.L., Karhapaa P., Miettinen H., Laakso M. Relationship of LDL size to insulin sensitivity in normoglycemic men. Arterioscler Thromb Vasc Biol. 17(7):1997;1447-1453.
4. Feingold K.R., Grunfeld C., Pang M., Doerrler W., Krauss R.M. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 12(12):1992;1496-1502.
5. Hirano T., Oi K., Sakai S., Kashiwazaki K., Adachi M., Yoshino G. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis. 141(1):1998;77-85.
6. Austin M.A., Edwards K.L. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 7(3):1996;167-171.
7. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276(11):1996;875-881.
8. Koba S., Hirano T. Small dense low-density lipoprotein in Japanese men with coronary artery disease. Ann Intern Med. 132(9):2000;762.
9. Slyper A.H. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA. 272(4):1994;305-308.
10. Galeano N.F., Milne R., Marcel Y.L., Walsh M.T., Levy E., Ngu'yen T.D., Gleeson A., Arad Y., Witte L., al Haideri M. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem. 269(1):1994;511-519.
11. de Graaf J., Hak Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 11(2):1991;298-306.
12. Tribble D.L., Krauss R.M., Lansberg M.G., Thiel P.M., van den Berg J.J. Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions. J Lipid Res. 36(4):1995;662-671.
13. Tan K.C., Shiu S.W., Chu B.Y. Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. Atherosclerosis. 145(2):1999;273-278.
14. Feher M.D., Caslake M., Foxton J., Cox A., Packard C.J. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes-Metab Res Rev. 15(6):1999;395-399.
15. Kugiyama K., Doi H., Takazoe K., Kawano H., Soejima H., Mizuno Y., Tsunoda R., Sakamoto T., Nakano T., Nakajima K., Ogawa H., Sugiyama S., Yoshimura M., Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 99(22):1999;2858-2860.
16. Devaraj S., Vega G., Lange R., Grundy S.M., Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med. 104(5):1998;445-450.
17. Masuoka H., Kamei S., Wagayama H., Ozaki M., Kawasaki A., Tanaka T., Kitamura M., Katoh S., Shintani U., Misaki M., Sugawa M., Ito M., Nakano T. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J. 139(2 Pt 1):2000;305-310.
18. Watanabe N., Taniguchi T., Taketoh H., Kitagawa Y., Namura H., Yoneda N., Kurimoto Y., Yamada S., Ishikawa Y. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes-Care. 22(1):1999;152-156.
19. Marcoux C., Tremblay M., Fredenrich A., Jacques H., Krimbou L., Nakajima K., Davignon J., Cohn J.S. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis. 139(1):1998;161-171.
20. Aoki T., Nishimura H., Nakagawa S., Kojima J., Suzuki H., Tamaki T., Wada Y., Yokoo N., Sato F., Kimata H., Kitahara M., Toyoda K., Sakashita M., Saito Y. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 47(8):1997;904-909.
21. Ooyen C., Zecca A., Bersino A.M., Catapano A.L. NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis. 145(1):1999;87-95.
22. Suzuki H., Aoki T., Tamaki T., Sato F., Kitahara M., Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis. 146(2):1999;259-270.
23. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., Tanaka A., Tada N., Nakamura H., Campos E., Havel R.J. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 223(1-2):1993;53-71.
24. Kazumi T., Kawaguchi A., Hozumi T., Nagao M., Iwahashi M., Hayakawa M., Ishihara K., Yoshino G. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis. 142(1):1999;113-119.
25. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 23(1):1982;97-104.
26. Siegel R.D., Cupples A., Schaefer E.J., Wilson P.W. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 45(10):1996;1267-1272.
27. Twickler T.B., Dallinga-Thie G.M., de Valk H.W., Schreuder P.C., Jansen H., Cabezas M.C., Erkelens D.W. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 20(11):2000;2422-2427.
28. Nagai T., Tomizawa T., Nakajima K., Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb. 7:2000;91-96.
29. Caixas A., Ordonez Llanos J., de Leiva A., Payes A., Homs R., Perez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 46(7):1997;1207-1213.
30. Halle M., Berg A., Garwers U., Baumstark M.W., Knisel W., Grathwohl D., Konig D., Keul J. Influence of 4 weeks' intervention by exercise and diet on low-density lipoprotein subfractions in obese men with type 2 diabetes. Metabolism. 48(5):1999;641-644.
31. Hoogerbrugge N., Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis. 146(1):1999;167-174.